Work

Current status of intranasal and inhaled COVID-19 vaccines

Year: 2026

Type: article

Abstract: The COVID-19 pandemic has accelerated the development of intranasal and inhaled COVID-19. vaccines. Four vector-based and one adjuvanted protein-based vaccines have been licenced. They have been shown to be safe. However, their ability to induce strong protective mucosal immunity in humans remains to be improved. Diversifying intranasal vaccine platforms, improving the delivery of vaccine components and determining mucosal correlates of protection could help in optimizing intranasal COVID-19 vaccine efficacy.

Source: npj Vaccines

DOI: 10.1038/s41541-026-01432-w

Authors: Stephanie Longet, Stephane Paul

Institutions: Lyon 1 Université, Centre National de la Recherche Scientifique, Inserm, Centre International de Recherche en Infectiologie, Centre Hospitalier Universitaire de Saint-Étienne

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,890